*Trypanosoma cruzi*, an haemoflagelate protozoa, is causative of Chagas disease, a neglected tropical disease ([@B20])) that is frequently encountered in people living in underdeveloped countries. The medical drug treatment currently available for Chagas disease is nifurtimox (Lampit^TM^, Bayer) and benznidazole (Rochagan^TM^, Roche); however, both drugs have limited efficacy on chronic stages and high toxicity ([@B5])). Additionally, there are different susceptibilities to those drugs among *T. cruzi* strains, which vary according to the geographical area ([@B11])). Therefore, there is an urgent need for the research and development of new drugs against *T. cruzi*.

The cytoskeleton of *T. cruzi* parasites is primarily composed of a subpellicular corset of microtubules ([@B8])) whose structure is vital for the shape, form, motility and survival/infectivity of the parasites. Actin is an important cytoskeletal protein that is present in all stages of *T. cruzi*, as demonstrated by [@B4]), on the body, flagellum and flagellar pocket regions. Therefore, any alteration induced by the effects of cytoskeletal disrupting agents, as found for benzimidazole chemicals, has a clear effect on the morphology of the parasites. JVG9 (5-chloro-1*H*-benzimidazole-2-thiol), an experimental benzimidazole derivative, has been shown to produce both trypanocidal effects against *T. cruzi* bloodstream trypomastigotes and to have low cellular toxicity compared with nifurtimox and other benzimidazole drugs ([@B7])). These effects are notable because of the well-recognised anthelmintic activity of benzimidazole-2-carbamates ([@B17])). In other studies, these chemicals inhibited the in vitro growth of the protozoa *Giardia lamblia* ([@B3])) and *Leishmania infantum* ([@B1]). Benzimidazole appears to interfere with microtubule dynamics by binding to β-tubulin ([@B10]) and there is evidence that these derivatives can inhibit the in vitro growth of some protozoa ([@B9]). Therefore, because these chemicals are potential anti-protozoa agents, our group has designed and synthesised a new series of 1*H*-benzimidazole derivatives and tested them against *G. lamblia*,*Entamoeba histolytica* and *Trichinella spiralis* to increase their efficacy ([@B17]). One of these compounds, the derivative JVG9, was found to be effective against *T. cruzi*bloodstream trypomastigotes ([@B7]); until now, however, its effects on the morphology and organisation of the parasite cytoskeleton have not been evaluated. We demonstrate in the present paper that JVG9 has a clear effect on the morphology of *T. cruzi* bloodstream trypomastigotes and produces alterations in the expression of the cytoskeletal proteins actin and tubulin.

MATERIALS AND METHODS
=====================

*Compound* - JVG9 was prepared as described previously. It was purified by column chromatography on silica gel and its chemical structure was confirmed by IR, 1H-NMR and MS data ([@B13], [@B17])).

*Parasites* - *T. cruzi* bloodstream trypomastigotes INC-5 strain (MHOM/MX/97/Inc-5) corresponding to the lineage I ([@B2])) were obtained via heart puncture of *T. cruzi*-infected NIH female, as described by [@B7]). Animal experiments were performed according to Official Mexican Standards (NOM-062-ZOO-1999).

*In vitro effects of JVG9 on parasites* - The effects on *T. cruzi* bloodstream trypomastigotes were evaluated as described previously ([@B7])). Briefly, bloodstream trypomastigote forms were incubated in 54.2 µm JVG9 diluted in dimethyl sulfoxide (DMSO) for 24 h. The final concentration of DMSO in the culture medium remained below 1%. The parasites were then removed and processed for scanning electron microscopy (SEM) and laser scanning confocal microscopy (LSCM). Parasites cultivated in the presence of DMSO (\< 1%) were considered negative controls.

*SEM* - Parasites were processed as previously described ([@B12])). Briefly, parasites were fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodilate (pH 7.2), subsequently washed three times with phosphate buffered saline (PBS), post-fixed with 2% osmium tetroxide (EM grade), dehydrated through a graded ethanol series, dried in a critical point drier and coated with ionised gold (15 nm thick). Images using taken with a Zeiss DSM-950 microscope adjusted to 15 kV. Image contrast was performed using the Adobe Photoshop v.8.0 software.

*Immunofluorescence assays* - Parasites were prepared as previously described ([@B18])) with slight modifications. Briefly, after parasites were washed with sterile buffer-PBS, they were placed onto poly-L-lysine coated coverslips. The samples were then fixed with 4% paraformaldehyde (w/v), permeabilised with 0.3% (v/v) Tween-20, blocked with 2% (w/v) bovine serum albumin in PBS and incubated overnight at 4ºC with a primary anti-α-tubulin antibody DM1A (1:100) (Santa Cruz Biotechnology Inc, USA) with fluorescein isothiocyanate-conjugated anti-mouse IgG (1:200) (ZYMED, USA) as a secondary antibody. Actin was revealed by an indirect immunoassay in which the primary antibody was a polyclonal anti-*T. cruzi* antibody (1:200) ([@B4])) and the secondary antibody was an anti-rabbit antibody coupled to biotin (1:30), followed by incubation with rhodamine-conjugated avidin (1:150) (Vector Laboratories, USA). DNA was stained with 4',6-diamidino-2-phenylindole (Sigma^®^) (1 mg/mL). Samples were mounted in mounting medium (DAKO^®^) and observed using a LSCM (TCS-MP5) Leica equipped with ultraviolet light, argon and helium-neon lasers and an objective lens (HCX PL APO lambda blue 63.0 x 1.40 OIL UV).

RESULTS
=======

With SEM, untreated bloodstream trypomastigotes appear to present a typical morphology of flagella, undulating membranes and a homogeneous surface ([Fig. 1A](#f01){ref-type="fig"}, [B](#f01){ref-type="fig"}). After treatment with JVG9, parasites were found to have important alterations in their topography, with a decreased flagellar size and, in several parasites, disruptions at their posterior ends ([Fig. 1C](#f01){ref-type="fig"}-[E](#f01){ref-type="fig"}). Additionally, several membrane protrusions appeared as blebs at the level of their cytoplasmic membranes ([Fig. 1F](#f01){ref-type="fig"}).

Fig. 1: scanning electron microscopy of bloodstream forms of *Trypanosoma cruzi*INC-5 strain. Control parasites showing typical morphology of the body and flagellum (A, B). Treatment of the parasites with 54.2 µm JVG9 during 24 h (C-F) induced the formation of blebs (asterisk), alterations in the anterior (open arrowhead) and posterior (arrow) ends, disruption of the flagellum (chevron symbol) and membrane undulating (arrowhead). Bar = 5 µm. RBC: red blood cell.

Using the technique of LSCM ([Fig. 2](#f02){ref-type="fig"}), JVG9 was found to restructure actin and α-tubulin in *T. cruzi* trypomastigotes. Untreated parasites ([Fig. 2](#f02){ref-type="fig"}) presented a different distribution of these cytoskeletal proteins in both their cellular bodies and flagella. The fluorescence pattern of actin was homogeneously distributed in parasites of the control group ([Fig. 2B](#f02){ref-type="fig"}) whereas in treated parasites the protein was found to be aggregated in patches on the body, but not in the flagellum ([Fig. 2B](#f02){ref-type="fig"}), and α-tubulin was distributed in clusters that were located primarily at the periphery ([Fig. 2C](#f02){ref-type="fig"}). Morphological changes have a strong correlation with the distribution of the microfilaments and microtubules in bloodstream trypomastigotes.

Fig. 2: laser scanning confocal microscopy images of bloodstream forms of *Trypanosoma cruzi*INC-5 strain. Upper panel: fluorescent staining of control parasite with DAPI (A), actin of *T. cruzi* (B), α-tubulin (C) MERGE (D) and Nomarsky illumination (E); bottom panel: bloodstream forms of *T. cruzi*INC-5 strain treated with JVG9 compound 54.2 µm during 24 h. The actin patches are indicating by arrows and clusters of α-tubulin are indicated by open arrowheads. Bar = 5 µm. F: flagellum; K: kinetoplast; N: nucleus.

DISCUSSION
==========

Because Chagas disease is still considered a public health problem and a neglected disease in many underdevelopment countries, the efforts to find effective drugs for its treatment continue. Many experimental compounds have been designed, produced and tested against *T. cruzi*, but many of them remain unused until their impact in the biology or the physiology of the parasite can be established. It is well known that the application of different approaches to the study of the cellular biology of the parasites has a great influence on drug development ([@B6], [@B14], [@B15], [@B16]). After the demonstration that the JVG9 is a benzimidazole derivative with trypanocidal activity ([@B7]), we here demonstrated that this compound produces alterations in the morphology and distribution of the cytoskeletal proteins actin and tubulin in bloodstream forms of the INC-5 strain. However, we noted that the concentration, at which the effects were observed in parasites, was six times lower than the LC50 reported in our previous work ([@B7]). We therefore decided to treat the parasites at 54.2 µm because this was the concentration at which we first observed an effect on cytoskeletal proteins such as actin and tubulin. Alternately, at higher concentrations, such as 320 µm, it was not possible to record any microscopic observations due the presence of precipitation.

It is possible that observed alterations on the parasite cytoskeletal proteins that produced changes in the morphology may be similar to those found after anti-cancer treatment. When *Leishmania amazonensis* and *T. cruzi* were evaluated with taxol and vinblastine, effects were clearly found on the membrane, with protrusions that resemble cellular surface blebs indicative of cell death mechanisms such as mitochondrial swelling, plasma membrane blebbing and the presence of autophagosome-like structures ([@B19]). If JVG9 is capable of triggering some form of this parasite death mechanism, this would be the first report of the involvement of alterations in the expression of cytoskeletal proteins in the presence of a benzimidazole-derivative compound. It would be worthwhile to evaluate the expression of cytoskeletal proteins using double-dimension electrophoresis, as published previously for actin ([@B4]) and to determine whether there are changes in the expression of actin and tubulin variants and whether they are the primary targets of these compounds. The effects of the designed JVG9 are a very good example of a structure-activity integration that produces better drugs through medicinal chemistry approaches. Additionally, it is an alternative approach showing how it is possible to redesign old drugs and thereby find novel compounds for the treatment of Chagas disease.
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